Chicago Biomedical Consortium’s Post

Disease of the Month: Mesothelioma  Greetings Readers! PharmaShots presents the Disease of the Month report, September Edition. This month, we have covered Mesothelioma, a type of cancer that affects the lining of the lungs, chest wall, and abdomen. #mesothelioma #diseaseofthemonth #awareness #pharmashots

At Artax Biopharma, we are developing first-in-class Nck modulators to treat T cell mediated autoimmune disease such as #psoriasis, #atopicdermatitis, and more. We're excited by the progress we've been making in the development of our first novel mechanism, AX-158, as we rapidly approach phase 2 trials for psoriasis treatment with first results expected in Q4 2024. We are simultaneously developing additional Nck modulator candidates for #autoimmunediseases with AX-194 undergoing preclinical testing to enter Phase 1 trials. Learn more about our candidate pipeline on our recently updated website here: https://lnkd.in/eqq3eSTK #clinincaltrials #immunology

A Breakthrough in Alzheimer’s Disease Diagnosis: Roche and Eli Lilly’s pTau217 Plasma Biomarker Test The FDA has given breakthrough status to a diagnostic test developed by Roche and Eli Lilly for Alzheimer's disease. The pTau217 plasma biomarker test aims to provide a reliable and efficient means of identifying the disease. It can deliver swift and accurate results, enabling earlier intervention and more proactive management strategies. The test holds promise in revolutionizing diagnosis and expediting patient recruitment for clinical trials. It offers a non-invasive and accessible alternative to current diagnostic methods. The collaboration between Roche and Eli Lilly represents a beacon of hope for individuals affected by Alzheimer's and their loved ones. The test could also lead to advancements in personalized treatment approaches. For more details please click the link! https://lnkd.in/dXFDNqYz #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

🚀 Dive into the Blockbuster Journey of Tepezza! 🌟 Discover how Horizon Therapeutics transformed thyroid eye disease treatment with Tepezza, setting a new standard in ophthalmic care. Don't miss this valuable case study, which provides launch and market entry lessons for the biopharma industry! Watch now: https://lnkd.in/dcEfA4tw #Tepezza #HorizonTherapeutics #OphthalmicBlockbuster #RareDisease #ThyroidEyeDisease #TepezzaCaseStudy #Pharma #HealthcareInnovation

Are you involved in cellular immunotherapy development? We want to hear from you! 🔬 We're eager to learn from biotech and pharma experts about current workflows, bottlenecks and pain points in the pre-clinical discovery and validation of cellular immunotherapies. ⚙️ Share your expertise with us by completing or sharing our brief survey via the link below. ⬇️ https://lnkd.in/dT3NF6eZ Visit us at www.avigen.co.uk or reach out to us directly to learn more or share your insights. #CellularImmunotherapy #Biotech #Pharma #ResearchAndDevelopment #Immunotherapy #CART #TCRT #DiscoveryAndValidation

More than 20 years of research has contributed to changing the treatment landscape for various blood cancers, like multiple myeloma. But there is still work to do. Our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases like blood cancer. Learn more about how we’re continuing to advance our unique approach to multiple myeloma research. #BloodCancerAwarenessMonth

🚨 FDA Issues Black Box Warning for CAR-T Therapy: A Critical Update for the Life Sciences Industry 🚨 The FDA has mandated a black box warning for CAR-T cell immunotherapies, a specialized treatment for certain blood cancers. This decision follows investigations into reports of T-cell malignancies associated with these therapies. 🔍 Companies Affected: Bristol-Myers Squibb Juno Therapeutics Janssen Biotech of Johnson & Johnson Novartis Kite Pharma 📌 Key Points: Black box warning, the most serious safety alert, indicates the potential for the therapy itself to cause cancer. FDA emphasizes that overall benefits outweigh the risks for approved uses but stresses the importance of patient awareness. #LifeSciences #QualityControl #QualityAssurance #FDAUpdate #CAR_TTherapy

Thoughts on this? >> Novartis brings Lutathera to adolescents with rare cancer in first for radioligand class >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #pharma #healthcare #biotech

Thoughts on this? >> Bristol Myers to discuss positive Opdivo-Yervoy Ph3 liver cancer data with health authorities >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharmaceutical #healthcare #pharma

Thoughts on this? >> KRAS cancer drug eased symptoms of rare and serious blood vessel condition in two patients, new study shows >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #healthcare #pharmaceutical